Invitrogen Corporation (IVGN) Launches Next-Generation Cell Culture Solution for Immunology Research
4/13/2009 9:41:32 AM
CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced the launch of GIBCO® OpTmizer™ T-cell Expansion SFM, a next-generation solution for culturing and expanding human T-cells that does not require the addition of serum to achieve optimal, cost-efficient results. OpTmizer SFM will enable scientists to advance their research on the central role that T-cells play in human immune response. These cells are widely studied by scientists conducting basic and clinical research, as well as biotech and pharmaceutical companies and organizations studying biodefense.
comments powered by